Vident Advisory’s 10x Genomics TXG Stock Holding History

Vident Advisory’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,998	Closed	-$162K	–	1738
2025 Q2	$162K	Buy	+13,998	New	+$128K	﹤0.01%	1527
2024 Q3	–	Sell	-11,999	Closed	-$233K	–	1553
2024 Q2	$233K	Buy	11,999 +4,171	+53%	+$109K	0.01%	1218
2024 Q1	$294K	Buy	7,828 +798	+11%	+$35.1K	0.01%	1033
2023 Q4	$393K	Sell	7,030 -117	-2%	-$5.09K	0.01%	890
2023 Q3	$295K	Buy	+7,147	New	+$372K	0.01%	918

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vident Advisory's TXG Position: Q3 2025 in Review

Vident Advisory sold out of 10x Genomics (TXG) in Q3 2025, closing a stake of 13,998 shares — an estimated $162K sold.

Vident Advisory first reported a position in TXG in Q3 2023 and held it in 5 quarters. The position peaked at $393K in Q4 2023. 317 funds tracked by Wall St. Rank hold TXG as of Q3 2025.

Vident Advisory reported no remaining 10x Genomics position as of Q3 2025 after selling out during the quarter.
Vident Advisory sold 13,998 10x Genomics shares in Q3 2025, an estimated $162K.
Vident Advisory first reported a position in 10x Genomics in Q3 2023 and held it in 5 quarters.
Vident Advisory's 10x Genomics position peaked at $393K in Q4 2023.
317 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2025.

Based on Vident Advisory's 13F filing for Q3 2025, filed 14 Nov 2025.